Vnitr Lek 2024, 70(5):318-325 | DOI: 10.36290/vnl.2024.063

News in gastroenterology, hepatology and digestive endoscopy

Dana Ďuricová1, 2, Ivana Mikoviny Kajzrlíková3, Kateřina Koą»álová4, 5, 6, Lucie Zdrhová7, 8, Ondřej Urban9, Václav ©míd10, Přemysl Falt9, Ilja Tachecí11
1 1II. interní gastroenterologická klinika, Fakultní nemocnice a Lékařská fakulta Univerzity Karlovy v Hradci Králové
2 Farmakologický ústav, 1. lékařská fakulta, Univerzita Karlova, Praha
3 Beskydské Gastrocentrum, Nemocnice ve Frýdku-Místku
4 Interní klinika, 1. lékařská fakulta, Univerzita Karlova a Ústřední vojenská nemocnice - Vojenská fakultní nemocnice, Praha
5 Ústav gastrointestinální onkologie, Ústřední vojenská nemocnice - Vojenská fakultní nemocnice, Praha
6 Univerzita obrany, Vojenská lékařská fakulta, Katedra vojenského vnitřního lékařství, Hradec Králové
7 I. interní klinika, Oddělení gastroenterologie a hepatologie, Fakultní nemocnice Plzeň
8 Centrum pohybové medicíny Pavla Koláře, Praha
9 II. interní klinika gastroenterologická a geriatrická, FN a LF UP Olomouc

Gastroenterology, digestive endoscopy, and hepatology are dynamically developing fields that bring many interesting and clinically important innovations and findings every year. The aim of this article is to provide an overview of these developments. The discussed topics include oesophageal diseases (specifically the treatment of eosinophilic esophagitis and reflux oesophageal disease) and the surveillance of patients at high risk of pancreatic cancer. In hepatology, much attention has been paid in recent years to the metabolic dysfunction-associated steatotic liver disease (MASLD), which is one of the most common chronic liver diseases. The last part of the article will focus on the updated Czech guidelines for colonoscopy.

Keywords: gastroenterology, hepatology, digestive endoscopy

Accepted: August 28, 2024; Published: September 4, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ďuricová D, Mikoviny Kajzrlíková I, Koą»álová K, Zdrhová L, Urban O, ©míd V, et al.. News in gastroenterology, hepatology and digestive endoscopy. Vnitr Lek. 2024;70(5):318-325. doi: 10.36290/vnl.2024.063.
Download citation

References

  1. Lucendo AJ, Molina-Infante J, Arias Á, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United Eur Gastroenterol J. 2017;5(3):335-358. doi:10.1177/2050640616689525. Go to original source... Go to PubMed...
  2. Dhar A, Haboubi HN, Attwood SE, et al. British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults. Gut. Published online May 23, 2022:gutjnl-2022-327326. doi:10.1136/gutjnl-2022-327326. Go to original source...
  3. Lucendo AJ, Arias Á, Molina-Infante J. Efficacy of Proton Pump Inhibitor Drugs for Inducing Clinical and Histologic Remission in Patients With Symptomatic Esophageal Eosinophilia: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2016;14(1):13-22.e1. doi:10.1016/j.cgh.2015. 07. 041. Go to original source...
  4. Cheng E, Zhang X, Huo X, et al. Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. Gut. 2013;62(6):824-832. doi:10.1136/gutjnl-2012-302250. Go to original source... Go to PubMed...
  5. Menclová A., Hojný M., Dulavová M, et al. Nové moľnosti léčby eozinofilní ezofagitidy pomocí magistraliter připravovaného léčiva. Praktické lékárenství. 2016(12):26-28. Go to original source...
  6. Lucendo AJ, Miehlke S, Schlag C, et al. Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial. Gastroenterology. 2019;157(1):74-86.e15. doi:10.1053/j.gastro.2019. 03. 025. Go to original source...
  7. Straumann A, Lucendo AJ, Miehlke S, et al. Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis. Gastroenterology. 2020;159(5):1672-1685.e5. doi:10.1053/j.gastro.2020. 07. 039 Go to original source...
  8. Arias Á, González-Cervera J, Tenias JM, Lucendo AJ. Efficacy of Dietary Interventions for Inducing Histologic Remission in Patients With Eosinophilic Esophagitis: A Systematic Review and Meta-analysis. Gastroenterology. 2014;146(7):1639-1648. doi:10.1053/j.gastro.2014. 02. 006. Go to original source...
  9. Dellon ES, Rothenberg ME, Collins MH, et al. Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis. N Engl J Med. 2022;387(25):2317-2330. doi:10.1056/NEJMoa2205982. Go to original source... Go to PubMed...
  10. Eusebi LH, Ratnakumaran R, Yuan Y, Solaymani-Dodaran M, Bazzoli F, Ford AC. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018;67(3):430-440. doi:10.1136/gutjnl-2016-313589. Go to original source... Go to PubMed...
  11. El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther. 2010;32(6):720-737. doi:10.1111/j.1365-2036.2010.04406.x. Go to original source... Go to PubMed...
  12. Garg SK, Gurusamy KS. Laparoscopic fundoplication surgery versus medical management for gastro-oesophageal reflux disease (GORD) in adults. Cochrane Database Syst Rev. 2015;2015(11):CD003243. doi:10.1002/14651858.CD003243.pub3. Go to original source... Go to PubMed...
  13. Utley DS, Kim M, Vierra MA, Triadafilopoulos G. Augmentation of lower esophageal sphincter pressure and gastric yield pressure after radiofrequency energy delivery to the gastroesophageal junction: A porcine model. Gastrointest Endosc. 2000;52(1):81-86. doi:10.1067/mge.2000.105981. Go to original source... Go to PubMed...
  14. Kalapala R, Singla N, Reddy DN. Endoscopic management of gastroesophageal reflux disease: Panacea for proton pump inhibitors dependent/refractory patients. Dig Endosc. 2022;34(4):687-699. doi:10.1111/den.14169. Go to original source... Go to PubMed...
  15. Lee DP, Chang KJ. Endoscopic Management of GERD. Dig Dis Sci. 2022;67(5):1455-1468. doi:10.1007/s10620-022-07390-2. Go to original source... Go to PubMed...
  16. Perry KA, Banerjee A, Melvin WS. Radiofrequency Energy Delivery to the Lower Esophageal Sphincter Reduces Esophageal Acid Exposure and Improves GERD Symptoms: A Systematic Review and Meta-analysis. Surg Laparosc Endosc Percutan Tech. 2012;22(4):283-288. doi:10.1097/SLE.0b013e3182582e92. Go to original source... Go to PubMed...
  17. Fass R, Cahn F, Scotti DJ, Gregory DA. Systematic review and meta-analysis of controlled and prospective cohort efficacy studies of endoscopic radiofrequency for treatment of gastroesophageal reflux disease. Surg Endosc. 2017;31(12):4865-4882. doi:10.1007/s00464-017-5431-2. Go to original source... Go to PubMed...
  18. Noar M, Squires P, Noar E, Lee M. Long-term maintenance effect of radiofrequency energy delivery for refractory GERD: a decade later. Surg Endosc. 2014;28(8):2323-2333. doi:10.1007/s00464-014-3461-6. Go to original source... Go to PubMed...
  19. Triadafilopoulos G, DiBaise JK, Nostrant TT, et al. The Stretta procedure for the treatment of GERD: 6 and 12 month follow-up of the U.S. open label trial. Gastrointest Endosc. 2002;55(2):149-156. doi:10.1067/mge.2002.121227. Go to original source... Go to PubMed...
  20. Lipka S, Kumar A, Richter JE. No evidence for efficacy of radiofrequency ablation for treatment of gastroesophageal reflux disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2015;13(6):1058-1067.e1. doi:10.1016/j.cgh.2014. 10. 013. Go to original source...
  21. Zerbib F, Sacher-Huvelin S, Coron E, et al. Randomised clinical trial: oesophageal radiofrequency energy delivery versus sham for PPI-refractory heartburn. Aliment Pharmacol Ther. 2020;52(4):637-645. doi:10.1111/apt.15936. Go to original source... Go to PubMed...
  22. Bitnar P, Stovicek J, Andel R, et al. Leg raise increases pressure in lower and upper esophageal sphincter among patients with gastroesophageal reflux disease. J Bodyw Mov Ther. 2016;20(3):518-524. doi:10.1016/j.jbmt.2015. 12. 002. Go to original source...
  23. Mittal RK, Shaffer HA, Parollisi S, Baggett L. Influence of breathing pattern on the esophagogastric junction pressure and esophageal transit. Am J Physiol-Gastrointest Liver Physiol. 1995;269(4):G577-G583. doi:10.1152/ajpgi.1995.269. 4. G577. Go to original source...
  24. Kahrilas PJ, Mittal RK, Bor S, et al. Chicago Classification update (v4.0): Technical review of high-resolution manometry metrics for EGJ barrier function. Neurogastroenterol Motil. 2021;33(10):e14113. doi:10.1111/nmo.14113. Go to original source... Go to PubMed...
  25. Festi D, Scaioli E, Baldi F, et al. Body weight, lifestyle, dietary habits and gastroesophageal reflux disease. World J Gastroenterol. 2009;15(14):1690-1701. doi:10.3748/wjg.15.1690 Go to original source... Go to PubMed...
  26. Zdrhova L, Bitnar P, Balihar K, et al. Breathing Exercises in Gastroesophageal Reflux Disease: A Systematic Review. Dysphagia. 2023;38(2):609-621. doi:10.1007/s00455-022-10494-6. Go to original source... Go to PubMed...
  27. National Cancer Institute. SEER Stat software. Bethesda, MD.
  28. Hur C, Tramontano AC, Dowling EC, et al. Early Pancreatic Ductal Adenocarcinoma Survival Is Dependent on Size: Positive Implications for Future Targeted Screening. Pancreas. 2016;45(7):1062-1066. doi:10.1097/MPA.0000000000000587. Go to original source... Go to PubMed...
  29. US Preventive Services Task Force, Owens DK, Davidson KW, et al. Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA. 2019;322(5):438. doi:10.1001/jama.2019.10232.Daląí literatura u autorů a na www.casopisvnitrnilekarstvi.cz Go to original source...
  30. Sharma A, Smyrk TC, Levy MJ, Topazian MA, Chari ST. Fasting Blood Glucose Levels Provide Estimate of Duration and Progression of Pancreatic Cancer Before Diagnosis. Gastroenterology. 2018;155(2):490-500.e2. doi:10.1053/j.gastro.2018. 04. 025. Go to original source...
  31. Frič P, ©edo A, ©krha J, et al. Časná detekce sporadického karcinomu pankreatu. Čas Lék Čes. 2016;(155):44-47.
  32. Sawhney MS, Calderwood AH, Thosani NC, et al. ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations. Gastrointest Endosc. 2022;95(5):817-826. doi:10.1016/j.gie.2021. 12. 001. Go to original source...
  33. Dbouk M, Katona BW, Brand RE, et al. The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival. J Clin Oncol Off J Am Soc Clin Oncol. 2022;40(28):3257-3266. doi:10.1200/JCO.22.00298. Go to original source... Go to PubMed...
  34. Overbeek KA, Levink IJM, Koopmann BDM, et al. Long-term yield of pancreatic cancer surveillance in high-risk individuals. Gut. 2022;71(6):1152-1160. doi:10.1136/gutjnl-2020-323611. Go to original source... Go to PubMed...
  35. Chhoda A, Vodusek Z, Wattamwar K, et al. Late-Stage Pancreatic Cancer Detected During High-Risk Individual Surveillance: A Systematic Review and Meta-Analysis. Gastroenterology. 2022;162(3):786-798. doi:10.1053/j.gastro.2021. 11. 021. Go to original source...
  36. Peters MLB, Eckel A, Seguin CL, et al. Cost-Effectiveness Analysis of Screening for Pancreatic Cancer Among High-Risk Populations. JCO Oncol Pract. Published online December 12, 2023:OP.23.00495. doi:10.1200/OP.23.00495. Go to original source... Go to PubMed...
  37. Vaněk P, Andraąina T, Bitnerová V, et al. Surveillance karcinomu pankreatu u osob s vysokým rizikem Stanovisko odborných společností. 2023(77):529-538.
  38. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151-171. doi:10.1016/j.jhep.2018. 09. 014. Go to original source...
  39. Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851-861. doi:10.1016/S2468-1253(22)00165-0. Go to original source... Go to PubMed...
  40. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542-1556. doi:10.1016/j.jhep.2023. 06. 003. Go to original source...
  41. Hardy T, Wonders K, Younes R, et al. The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. Contemp Clin Trials. 2020;98:106175. doi:10.1016/j.cct.2020.106175. Go to original source... Go to PubMed...
  42. Quek J, Chan KE, Wong ZY, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(1):20-30. doi:10.1016/S2468-1253(22)00317-X. Go to original source... Go to PubMed...
  43. Marchesini G, Day CP, Dufour JF, et al. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-1402. doi:10.1016/j.jhep.2015. 11. 004. Go to original source...
  44. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357. doi:10.1002/hep.29367. Go to original source... Go to PubMed...
  45. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. doi:10.1097/HEP.0000000000000323. Go to original source... Go to PubMed...
  46. Barr RG, Wilson SR, Rubens D, Garcia-Tsao G, Ferraioli G. Update to the Society of Radiologists in Ultrasound Liver Elastography Consensus Statement. Radiology. 2020;296(2):263-274. doi:10.1148/radiol.2020192437. Go to original source... Go to PubMed...
  47. Drenth JPH, Schattenberg JM. The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success. Expert Opin Investig Drugs. 2020;29(12):1365-1375. doi:10.1080/13543784.2020.1839888. Go to original source... Go to PubMed...
  48. Athyros VG, Alexandrides TK, Bilianou H, et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism. 2017;71:17-32. doi:10.1016/j.metabol.2017. 02. 014. Go to original source...
  49. Pastori D, Pani A, Di Rocco A, et al. Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis. Br J Clin Pharmacol. 2022;88(2):441-451. doi:10.1111/bcp.14943. Go to original source... Go to PubMed...
  50. Kuchay MS, Misra A. Role of diabetologists in the management of nonalcoholic fatty liver disease: Primary prevention and screening/management of fibrosis and cirrhosis. Diabetes Metab Syndr Clin Res Rev. 2022;16(3):102446. doi:10.1016/j.dsx.2022.102446. Go to original source... Go to PubMed...
  51. Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384(12):1113-1124. doi:10.1056/NEJMoa2028395. Go to original source... Go to PubMed...
  52. Harrison SA, Bedossa P, Guy CD, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390(6):497-509. doi:10.1056/NEJMoa2309000. Go to original source... Go to PubMed...
  53. Duąek L, Muľík J, Kubásek, M. Epidemiologie zhoubných nádorů v České republice 2023 [online].
  54. Falt P, Urban O, Suchánek S, et al. Doporučené postupy České gastroenterologické společnosti ČLS JEP pro diagnostickou a terapeutickou koloskopii. Gastroent Hepatol. 2016(70(6)):523-538. Go to original source...
  55. Falt P, Cyrany J, Kunovský L, et al. Doporučené postupy České gastroenterologické společnosti ČLS JEP pro diagnostickou a terapeutickou koloskopii - aktualizované vydání 2024. Gastroent Hepatol. 2024(78(3)):197-235. Go to original source...
  56. Hassan C, Antonelli G, Dumonceau JM, et al. Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2020. Endoscopy. 2020;52(08):687-700. doi:10.1055/a-1185-3109. Go to original source... Go to PubMed...
  57. Mangas-Sanjuan C, Jover R. Familial colorectal cancer. Best Pract Res Clin Gastroenterol. 2022;58-59:101798. doi:10.1016/j.bpg.2022.101798. Go to original source... Go to PubMed...
  58. Hassan C, East J, Radaelli F, et al. Bowel preparation for colonoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2019. Endoscopy. 2019;51(08):775-794. doi:10.1055/a-0959-0505. Go to original source... Go to PubMed...
  59. Kaminski MF, Thomas-Gibson S, Bugajski M, et al. Performance measures for lower gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. Endoscopy. 2017;49(4):378-397. doi:10.1055/s-0043-103411. Go to original source... Go to PubMed...
  60. Cyrany J, Malý R, Rejchrt S, Tachecí I. Antithrombotic therapy and digestive endoscopy. Vnitr Lek. 2022;68(8):538-542. doi:10.36290/vnl.2022.113. Go to original source... Go to PubMed...
  61. Ferlitsch M, Hassan C, Bisschops R, et al. Colorectal polypectomy and endoscopic mucosal resection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2024. Endoscopy. Published online April 26, 2024:a-2304-3219. doi:10.1055/a-2304-3219. Go to original source... Go to PubMed...
  62. Falt P. Endoscopic treatment of early colorectal cancer. Vnitr Lek. 2022;68(6):355-362. doi:10.36290/vnl.2022.075 Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.